ArticleActa obstetricia et gynecologica Scandinavica2025
Health-related quality of life in adult-type ovarian granulosa cell tumor survivors.
Article in Acta obstetricia et gynecologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Health-related quality of life in adult-type ovarian granulosa cell tumor survivors.Acta obstetricia et gynecologica Scandinavica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionAdult-type granulosa cell tumor (AGCT) is a rare, slow-growing ovarian neoplasm with a tendency for late relapses. Surgery is the cornerstone of the treatment, and chemotherapy and hormonal treatment are administered in advanced and recurrent disease. The objective of our study was to assess health-related quality of life (HRQoL) in AGCT survivors. MATERIAL AND
methods15D and European Organization for Research and Treatment of Cancer (EORTC-QLQ-C30) questionnaires were collected from our prospective AGCT patient cohort, consisting of 171 AGCT survivors. The age-standardized general female population was used as a reference for 15D comparison. Clinical and sociodemographic variables and EORTC-QLQ-C30 symptom and function scales were used as independent variables in regression analysis explaining the variance in the 15D score.
resultsEighty-six women (50.3%), with a mean age of 68 years, returned the questionnaires. The HRQoL of AGCT survivors was similar to the general female population. The mean 15D score in our patient group was 0.891 (reference population score 0.899, p = 0.454). The scores were slightly lower on the 15D dimensions of excretion and sexual activity, whereas mental function scores were higher compared with the reference population. A history of tumor recurrence, an increasing number of other chronic illnesses, and financial difficulties each diminished HRQoL in our patient cohort. Regressing the EORTC variables on 15D produced a high explanatory power and accurate predictions of 15D scores.
conclusionsHRQoL of AGCT survivors was equal to that of the controls. Mapping EORTC-QLQ-C30 to 15D validly predicted 15D scores in AGCT survivors, confirming the usefulness of generic 15D for estimating quality-adjusted life years in cancer patient trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.